Home » Topics » BioWorld Science, Infection

BioWorld Science, Infection
RSS

Bavarian Nordic reports preclinical data on COVID-19 vaccine candidate ABNCoV2

March 8, 2021

Abivax stops phase IIb/III trial of ABX-464 in high-risk COVID-19 based on DSMB recommendation

March 8, 2021

Aligos Therapeutics discloses new antivrals for hepatitis

March 8, 2021

Innovation studies brilacidin in phase II trial for hospitalized patients with COVID-19

March 8, 2021

CytoDyn reports phase III data on leronlimab in critically ill COVID-19 patients

March 8, 2021

Neumifil is efficacious in hamster model of COVID-19 infection

March 8, 2021

FDA approves phase III study of proxalutamide in COVID-19

March 8, 2021

Study sponsors discontinue testing of razuprotafib in I-SPY COVID trial

March 8, 2021

Headless hemagglutinin induces broad influenza antibodies

March 8, 2021

TurnSole initiates phase I/II study of TS-020 in hospitalized COVID-19 patients

March 5, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...